Sirolimus and everolimus pathway: Reviewing candidate genes influencing their intracellular effects

International Journal of Molecular Sciences

Volumn 17, Issue 5, 2016, Pages

  Granata, Simona ^a   Dalla Gassa, Alessandra ^a   Carraro, Amedeo ^a   Brunelli, Matteo ^a   Stallone, Giovanni ^b   Lupo, Antonio ^a   Zaza, Gianluigi ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Everolimus; Genes; mTOR inhibitors; Sirolimus; Transplantation

Indexed keywords

CYCLOSPORIN A; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; VASCULOTROPIN; MICRORNA; TARGET OF RAPAMYCIN KINASE;

ANGIOGENESIS; CELL CYCLE ARREST; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR MEMBRANE; MITOCHONDRIAL BIOGENESIS; PHARMACOGENETICS; PHOSPHORYLATION; PROTEIN INTERACTION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETIC ASSOCIATION STUDY; INTRACELLULAR SPACE; METABOLISM;

ANIMALS; EVEROLIMUS; GENETIC ASSOCIATION STUDIES; HUMANS; INTRACELLULAR SPACE; MICRORNAS; PHARMACOGENETICS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84968719123     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17050735     Document Type: Review

References (245)

1. Kirchner, G.I.; Meier-Wiedenbach, I.; Manns, M.P. Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. 2004, 43, 83-95. [CrossRef] [PubMed]
2. Sehgal, S.N. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biochem. 1998, 31, 335-340. [CrossRef]
3. Kelly, P.A.; Gruber, S.A.; Behbod, F.; Kahan, B.D. Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy 1997, 17, 1148-1156. [PubMed]
4. Morath, C.; Arns, W.; Schwenger, V.; Mehrabi, A.; Fonouni, H.; Schmidt, J.; Zeier, M. Sirolimus in renal transplantation. Nephrol. Dial. Transplant. 2007, 22 (Suppl. 8), viii61-viii65. [CrossRef] [PubMed]
5. Paoletti, E.; Ratto, E.; Bellino, D.; Marsano, L.; Cassottana, P.; Cannella, G. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction. J. Nephrol. 2012, 25, 709-718. [CrossRef] [PubMed]
6. Schena, F.P.; Pascoe, M.D.; Alberu, J.; del Carmen Rial, M.; Oberbauer, R.; Brennan, D.C.; Campistol, J.M.; Racusen, L.; Polinsky, M.S.; Goldberg-Alberts, R. et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009, 87, 233-242. [CrossRef] [PubMed]
7. Mota, A.; Arias, M.; Taskinen, E.I.; Paavonen, T.; Brault, Y.; Legendre, C.; Claesson, K.; Castagneto, M.; Campistol, J.M.; Hutchinson, B. et al. Sirolimus-based therapy flowing early cyclosporine withdrawal provides significantly improved renal histology and function at three years. Am. J. Transplant. 2004, 2, 953-961. [CrossRef] [PubMed]
8. Russ, G.; Segoloni, G.; Oberbauer, R.; Legendre, C.; Mota, A.; Eris, J.; Grinyó, J.M.; Friend, P.; Lawen, J.; Hartmann, A. et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 2005, 80, 1204-1211. [CrossRef] [PubMed]
9. Stallone, G.; Infante, B.; Schena, A.; Battaglia, M.; Ditonno, P.; Loverre, A.; Gesualdo, L.; Schena, F.P.; Grandaliano, G. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J. Am. Soc. Nephrol. 2005, 16, 3755-3762. [CrossRef] [PubMed]
10. Lebranchu, Y.; Thierry, A.; Touopance, O.; Westeel, P.F.; Etienne, I.; Thervet, E.; Moulin, B.; Frouget, T.; Le Meur, Y.; Glotz, D. et al. Efficacy on renal function of early conversion to sirolimus 3 months after renal transplantation: Concept study. Am. J. Transplant. 2009, 2, 1115-1123. [CrossRef] [PubMed]
11. Nashan, B.; Gaston, R.; Emery, V.; Säemann, M.D.; Mueller, N.J.; Couzi, L.; Dantal, J.; Shihab, F.; Mulgaonkar, S.; Seun Kim, Y. et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012, 93, 1075-1085. [CrossRef] [PubMed]
12. Tedesco-Silva, H.; Cibrik, D.; Johnston, T.; Lackova, E.; Mange, K.; Panis, C.; Walker, R.; Wang, Z.; Zibari, G.; Kim, Y.S. Everolimus plus reduced-exposure CsA versus mycopholic acid plus standard-exposure CsA in renal-transplant recipients. Am. J. Transplant. 2010, 2, 1401-1413. [CrossRef] [PubMed]
13. Suwelack, B.; Malyar, V.; Koch, M.; Sester, M.; Sommerer, C. The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. Transplant. Rev. 2012, 2, 201-211. [CrossRef] [PubMed]
14. Legendre, C.; Campistol, J.M.; Squifflet, J.P.; Burke, J.T.; Sirolimus European Renal Transplant Study Group. Cardiovascular risk factors of sirolimus compared with cyclosporine: Early experience from two randomized trials in renal transplantation. Transplant. Proc. 2003, 35 (Suppl. 3), 151S-153S. [CrossRef]
15. Joannidès, R.; Monteil, C.; de Ligny, B.H.; Westeel, P.F.; Iacob, M.; Thervet, E.; Barbier, S.; Bellien, J.; Lebranchu, Y.; Seguin, S.G. et al. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am. J. Transplant. 2011, 11, 2414-2422. [CrossRef] [PubMed]
16. Morales, J.M. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. Kidney Int. Suppl. 2002, 62, S81-S87. [CrossRef] [PubMed]
17. Paoletti, E.; Marsano, L.; Bellino, D.; Cassottana, P.; Cannella, G. Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: A 1 year, randomized, controlled trial. Transplantation 2012, 93, 503-508. [CrossRef] [PubMed]
18. Trinh, X.B.; Tjalma, W.A.; Vermeulen, P.B.; van den Eynden, G.; van der Auwera, I.; van Laere, S.J.; Helleman, J.; Berns, E.M.; Dirix, L.Y.; van Dam, P.A. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br. J. Cancer 2009, 100, 971-978. [CrossRef] [PubMed]
19. Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 2271-2281. [CrossRef] [PubMed]
20. Motzer, R.J.; Escudier, B.; Oudard, S.; Hutson, T.E.; Porta, C.; Bracarda, S.; Grünwald, V.; Thompson, J.A.; Figlin, R.A.; Hollaender, N. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372, 449-456. [CrossRef]
21. Garcia-Echeverria, C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg. Med. Chem. Lett. 2010, 20, 4308-4312. [CrossRef] [PubMed]
22. Zhang, Y.; Zheng, X.F. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle 2012, 11, 594-603. [CrossRef] [PubMed]
23. Wander, S.A.; Hennessy, B.T.; Slingerland, J.M. Nextgeneration mTOR inhibitors in clinical oncology: How pathway complexity informs therapeutic strategy. J. Clin. Investig. 2011, 121, 1231-1241. [CrossRef] [PubMed]
24. ANZDATA Registry. 36th Report, Chapter 8: Transplantation. Australia and New Zealand Dialysis and Transplant Registry: Adelaide, Australia, 2014. Available online: http://www.anzdata.org.au (accessed on 8 March 2016).
25. Ventura-Aguiar, P.; Campistol, J.M.; Diekmann, F. Safety of mTOR inhibitors in adult solid organ transplantation. Expert Opin. Drug Saf. 2016, 28, 1-17. [CrossRef] [PubMed]
26. Oberbauer, R.; Kreis, H.; Johnson, R.W.; Mota, A.; Claesson, K.; Ruiz, J.C.; Wilczek, H.; Jamieson, N.; Henriques, A.C.; Paczek, L. et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003, 76, 364-370. [CrossRef] [PubMed]
27. Campistol, J.M.; Eris, J.; Oberbauer, R.; Friend, P.; Hutchinson, B.; Morales, J.M.; Claesson, K.; Stallone, G.; Russ, G.; Rostaing, L. et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J. Am. Soc. Nephrol. 2006, 2, 581-589. [CrossRef] [PubMed]
28. Alberú, J.; Pascoe, M.D.; Campistol, J.M.; Schena, F.P.; Rial Mdel, C.; Polinsky, M.; Neylan, J.F.; Korth-Bradley, J.; Goldberg-Alberts, R.; Maller, E.S. et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011, 92, 303-310. [CrossRef] [PubMed]
29. Hara, K.; Maruki, Y.; Long, X.; Yoshino, K.; Oshiro, N.; Hidayat, S.; Tokunaga, C.; Avruch, J.; Yonezawa, K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002, 110, 177-189. [CrossRef]
30. Kim, D.H.; Sarbassov, D.D.; Ali, S.M.; King, J.E.; Latek, R.R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D.M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110, 163-175. [CrossRef]
31. Kim, D.H.; Sarbassov, D.D.; Ali, S.M.; Latek, R.R.; Guntur, K.V.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D.M. GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 2003, 11, 895-904. [CrossRef]
32. Thedieck, K.; Polak, P.; Kim, M.L.; Molle, K.D.; Cohen, A.; Jenö, P.; Arrieumerlou, C.; Hall, M.N. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS ONE 2007, 2, e1217. [CrossRef] [PubMed]
33. Peterson, T.R.; Laplante, M.; Thoreen, C.C.; Sancak, Y.; Kang, S.A.; Kuehl, W.M.; Gray, N.S.; Sabatini, D.M. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137, 873-886. [CrossRef] [PubMed]
34. Inoki, K.; Li, Y.; Xu, T.; Guan, K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003, 17, 1829-1834. [CrossRef] [PubMed]
35. Tee, A.R.; Manning, B.D.; Roux, P.P.; Cantley, L.C.; Blenis, J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 2003, 13, 1259-1268. [CrossRef]
36. Dibble, C.C.; Manning, B.D. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat. Cell Biol. 2013, 15, 555-564. [CrossRef] [PubMed]
37. Shimobayashi, M.; Hall, M.N. Making new contacts: The mTOR network in metabolism and signaling crosstalk. Nat. Rev. Mol. Cell Biol. 2014, 15, 155-162. [CrossRef] [PubMed]
38. Guertin, D.A.; Sabatini, D.M. An expanding role for mTOR in cancer. Trends Mol. Med. 2005, 11, 353-361. [CrossRef] [PubMed]
39. Jacinto, E.; Loewith, R.; Schmidt, A.; Lin, S.; Rüegg, M.A.; Hall, A.; Hall, M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 2004, 6, 1122-1128. [CrossRef] [PubMed]
40. Pearce, L.R.; Huang, X.; Boudeau, J.; Pawłowski, R.; Wullschleger, S.; Deak, M.; Ibrahim, A.F.; Gourlay, R.; Magnuson, M.A.; Alessi, D.R. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem. J. 2007, 405, 513-522. [CrossRef] [PubMed]
41. Sarbassov, D.D.; Ali, S.M.; Sengupta, S.; Sheen, J.H.; Hsu, P.P.; Bagley, A.F.; Markhard, A.L.; Sabatini, D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22, 159-168. [CrossRef] [PubMed]
42. Huang, K.; Fingar, D.C. Growing knowledge of the mTOR signaling network. Semin. Cell Dev. Biol. 2014, 36, 79-90. [CrossRef] [PubMed]
43. Laplante, M.; Sabatini, D.M. mTOR signaling in growth control and disease. Cell 2012, 149, 274-293. [CrossRef] [PubMed]
44. Ikenoue, T.; Inoki, K.; Yang, Q.; Zhou, X.; Guan, K.L. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 2008, 27, 1919-1931. [CrossRef] [PubMed]
45. Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307, 1098-1101. [CrossRef] [PubMed]
46. Sarbassov, D.D.; Ali, S.M.; Kim, D.H.; Guertin, D.A.; Latek, R.R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004, 14, 1296-1302. [CrossRef] [PubMed]
47. Facchinetti, V.; Ouyang, W.; Wei, H.; Soto, N.; Lazorchak, A.; Gould, C.; Lowry, C.; Newton, A.C.; Mao, Y.; Miao, R.Q. et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase, C. EMBO J. 2008, 27, 1932-1943. [CrossRef] [PubMed]
48. Liu, L.; Das, S.; Losert, W.; Parent, C.A. mTORC2 regulates neutrophil chemotaxis in a cAMP-and RhoA-dependent fashion. Dev. Cell 2010, 19, 845-857. [CrossRef] [PubMed]
49. García-Martínez, J.M.; Alessi, D.R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 2008, 416, 375-385. [CrossRef] [PubMed]
50. Lamouille, S.; Connolly, E.; Smyth, J.W.; Akhurst, R.J.; Derynck, R. TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J. Cell Sci. 2012, 125 Pt 5, 1259-1273. [CrossRef] [PubMed]
51. Masola, V.; Carraro, A.; Zaza, G.; Bellin, G.; Montin, U.; Violi, P.; Lupo, A.; Tedeschi, U. Epithelial to mesenchymal transition in the liver field: The double face of Everolimus in vitro. BMC Gastroenterol. 2015, 15, 118. [CrossRef] [PubMed]
52. Zaza, G.; Masola, V.; Granata, S.; Bellin, G.; Dalla Gassa, A.; Onisto, M.; Gambaro, G.; Lupo, A. Sulodexide alone or in combination with low doses of everolimus inhibits the hypoxia-mediated epithelial to mesenchymal transition in human renal proximal tubular cells. J. Nephrol. 2015, 28, 431-440. [CrossRef] [PubMed]
53. Masola, V.; Zaza, G.; Granata, S.; Gambaro, G.; Onisto, M.; Lupo, A. Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: Key role of heparanase. J. Transl. Med. 2013, 11, 292. [CrossRef] [PubMed]
54. Schreiber, K.H.; Ortiz, D.; Academia, E.C.; Anies, A.C.; Liao, C.Y.; Kennedy, B.K. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. Aging Cell 2015, 14, 265-273. [CrossRef] [PubMed]
55. Oshiro, N.; Yoshino, K.; Hidayat, S.; Tokunaga, C.; Hara, K.; Eguchi, S.; Avruch, J.; Yonezawa, K. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 2004, 9, 359-366. [CrossRef] [PubMed]
56. Kalinsky, K.; Heguy, A.; Bhanot, U.K.; Patil, S.; Moynahan, M.E. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Res. Treat. 2011, 129, 635-643. [CrossRef] [PubMed]
57. Pasqualetti, F.; Bocci, G.; Mey, V.; Menghini, V.; Montrone, S.; Cocuzza, P.; Ferrazza, P.; Seccia, V.; Delishaj, D.; Orlandini, C. et al. Akt1 rs2498801 is related to survival in head and neck squamous cell cancer treated with radiotherapy. Anticancer Res. 2015, 35, 269-271. [PubMed]
58. Rossi, S.; Motta, C.; Studer, V.; Monteleone, F.; de Chiara, V.; Buttari, F.; Barbieri, F.; Bernardi, G.; Battistini, L.; Cutter, G. et al. A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. Mult. Scler. J. 2013, 19, 59-68. [CrossRef] [PubMed]
59. Liu, S.Y.; Zhao, H.D.; Wang, J.L.; Huang, T.; Tian, H.W.; Yao, L.F.; Tao, H.; Chen, Z.W.; Wang, C.Y.; Sheng, S.T. et al. Association between polymorphisms of the AKT1 gene promoter and risk of the Alzheimer’s disease in a Chinese Han Population with type 2 diabetes. CNS Neurosci. Ther. 2015, 21, 619-625. [CrossRef] [PubMed]
60. Wang, Y.; Lin, L.; Xu, H.; Li, T.; Zhou, Y.; Dan, H.; Jiang, L.; Liao, G.; Zhou, M.; Li, L. et al. Genetic variants in AKT1 gene were associated with risk and survival of OSCC in Chinese Han Population. J. Oral Pathol. Med. 2015, 44, 45-50. [CrossRef] [PubMed]
61. Wang, X.; Lin, Y.; Lan, F.; Yu, Y.; Ouyang, X.; Wang, X.; Huang, Q.; Wang, L.; Tan, J.; Zheng, F. A GG allele of 31-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer. J. Cancer Res. Clin. Oncol. 2014, 140, 1399-1411. [CrossRef] [PubMed]
62. Wang, L.; Yamaguchi, S.; Burstein, M.D.; Terashima, K.; Chang, K.; Ng, H.K.; Nakamura, H.; He, Z.; Doddapaneni, H.; Lewis, L. et al. Novel somatic and germline mutations in intracranial germ cell tumours. Nature 2014, 511, 241-245. [CrossRef] [PubMed]
63. Li, Q.; Yang, J.; Yu, Q.; Wu, H.; Liu, B.; Xiong, H.; Hu, G.; Zhao, J.; Yuan, X.; Liao, Z. Associations between single-nucleotide polymorphisms in the PI3K-PTEN-AKT-mTOR pathway and increased risk of brain metastasis in patients with non-small cell lung cancer. Clin. Cancer Res. 2013, 19, 6252-6260. [CrossRef] [PubMed]
64. Howitt, B.E.; Sholl, L.M.; Dal Cin, P.; Jia, Y.; Yuan, L.; MacConaill, L.; Lindeman, N.; Kuo, F.; Garcia, E.; Nucci, M.R. et al. Targeted genomic analysis of Müllerian adenosarcoma. J. Pathol. 2015, 235, 37-49. [CrossRef] [PubMed]
65. McKenzie, J.A.; Witkowski, S.; Ludlow, A.T.; Roth, S.M.; Hagberg, J.M. AKT1 G205T genotype influences obesity-related metabolic phenotypes and their responses to aerobic exercise training in older Caucasians. Exp. Physiol. 2011, 96, 338-347. [CrossRef] [PubMed]
66. Pawlikowska, L.; Hu, D.; Huntsman, S.; Sung, A.; Chu, C.; Chen, J.; Joyner, A.H.; Schork, N.J.; Hsueh, W.C.; Reiner, A.P. et al. Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell 2009, 8, 460-472. [CrossRef] [PubMed]
67. Hildebrandt, M.A.; Yang, H.; Hung, M.C.; Izzo, J.G.; Huang, M.; Lin, J.; Ajani, J.A.; Wu, X. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J. Clin. Oncol. 2009, 27, 857-871. [CrossRef] [PubMed]
68. Goodarzi, M.O.; Jones, M.R.; Chen, Y.D.; Azziz, R. First evidence of genetic association between AKT2 and polycystic ovary syndrome. Diabetes Care 2008, 31, 2284-2287. [CrossRef] [PubMed]
69. Wang, L.E.; Ma, H.; Hale, K.S.; Yin, M.; Meyer, L.A.; Liu, H.; Li, J.; Lu, K.H.; Hennessy, B.T.; Li, X. et al. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J. Cancer Res. Clin. Oncol. 2012, 138, 377-385. [CrossRef] [PubMed]
70. Harris, S.L.; Gil, G.; Robins, H.; Hu, W.; Hirshfield, K.; Bond, E.; Bond, G.; Levine, A.J. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc. Natl. Acad. Sci. USA 2005, 102, 16297-16302. [CrossRef] [PubMed]
71. Yarden, R.I.; Friedman, E.; Metsuyanim, S.; Olender, T.; Ben-Asher, E.; Papa, M.Z. Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Mol. Carcinog. 2010, 49, 545-555. [CrossRef] [PubMed]
72. Slattery, M.L.; Lundgreen, A.; Herrick, J.S.; Caan, B.J.; Potter, J.D.; Wolff, R.K. Diet and colorectal cancer: Analysis of a candidate pathway using SNPS, haplotypes, and multi-gene assessment. Nutr. Cancer 2011, 63, 1226-1234. [CrossRef] [PubMed]
73. Chen, M.; Gu, J.; Delclos, G.L.; Killary, A.M.; Fan, Z.; Hildebrandt, M.A.; Chamberlain, R.M.; Grossman, H.B.; Dinney, C.P.; Wu, X. Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis 2010, 31, 1387-1391. [CrossRef] [PubMed]
74. Hosgood, H.D., III; Menashe, I.; Shen, M.; Yeager, M.; Yuenger, J.; Rajaraman, P.; He, X.; Chatterjee, N.; Caporaso, N.E.; Zhu, Y. et al. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway. Carcinogenesis 2008, 29, 1938-1943. [CrossRef] [PubMed]
75. Lin, J.; Wang, J.; Greisinger, A.J.; Grossman, H.B.; Forman, M.R.; Dinney, C.P.; Hawk, E.T.; Wu, X. Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer. Cancer Prev. Res. 2010, 3, 505-517. [CrossRef] [PubMed]
76. Lavender, N.A.; Rogers, E.N.; Yeyeodu, S.; Rudd, J.; Hu, T.; Zhang, J.; Brock, G.N.; Kimbro, K.S.; Moore, J.H.; Hein, D.W. et al. Interaction among apoptosis-associated sequence variants and joint effects on aggressive prostate cancer. BMC Med. Genomics 2012, 5, 11. [CrossRef] [PubMed]
77. Shu, X.; Lin, J.; Wood, C.G.; Tannir, N.M.; Wu, X. Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk. J. Natl. Cancer Inst. 2013, 105, 424-432. [CrossRef] [PubMed]
78. Ellsworth, K.A.; Moon, I.; Eckloff, B.W.; Fridley, B.L.; Jenkins, G.D.; Batzler, A.; Biernacka, J.M.; Abo, R.; Brisbin, A.; Ji, Y. et al. FKBP5 genetic variation: Association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet. Genom. 2013, 23, 156-166. [CrossRef] [PubMed]
79. Woillard, J.B.; Kamar, N.; Rousseau, A.; Rostaing, L.; Marquet, P.; Picard, N. Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients. Pharmacogenet. Genom. 2012, 22, 725-732. [CrossRef] [PubMed]
80. Xu, M.; Tao, G.; Kang, M.; Gao, Y.; Zhu, H.; Gong, W.; Wang, M.; Wu, D.; Zhang, Z.; Zhao, Q. A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population. PLoS ONE 2013, 8, e60080. [CrossRef] [PubMed]
81. Cao, Q.; Ju, X.; Li, P.; Meng, X.; Shao, P.; Cai, H.; Wang, M.; Zhang, Z.; Qin, C.; Yin, C. A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk. PLoS ONE 2012, 7, e50302. [CrossRef] [PubMed]
82. He, J.; Wang, M.Y.; Qiu, L.X.; Zhu, M.L.; Shi, T.Y.; Zhou, X.Y.; Sun, M.H.; Yang, Y.J.; Wang, J.C.; Jin, L. et al. Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population. Mol. Carcinog. 2013, 52 (Suppl. 1), E70-E79. [CrossRef] [PubMed]
83. Slattery, M.L.; Herrick, J.S.; Lundgreen, A.; Fitzpatrick, F.A.; Curtin, K.; Wolff, R.K. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Carcinogenesis 2010, 31, 1604-1611. [CrossRef] [PubMed]
84. Bodnar, L.; Stec, R.; Cierniak, S.; Synowiec, A.; Wcisło, G.; Jesiotr, M.; Koktysz, R.; Kozłowski, W.; Szczylik, C. Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines. Ann. Oncol. 2015, 26, 1385-1389. [CrossRef] [PubMed]
85. Pérez-Tenorio, G.; Alkhori, L.; Olsson, B.; Waltersson, M.A.; Nordenskjöld, B.; Rutqvist, L.E.; Skoog, L.; Stål, O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin. Cancer Res. 2007, 13, 3577-3584. [CrossRef] [PubMed]
86. Ollikainen, M.; Gylling, A.; Puputti, M.; Nupponen, N.N.; Abdel-Rahman, W.M.; Butzow, R.; Peltomäki, P. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int. J. Cancer 2007, 121, 915-920. [CrossRef] [PubMed]
87. Wik, E.; Birkeland, E.; Trovik, J.; Werner, H.M.; Hoivik, E.A.; Mjos, S.; Krakstad, C.; Kusonmano, K.; Mauland, K.; Stefansson, I.M. et al. High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clin. Cancer Res. 2013, 19, 2331-2341. [CrossRef] [PubMed]
88. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S.M.; Riggins, G.J. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304, 554. [CrossRef] [PubMed]
89. Janku, F.; Tsimberidou, A.M.; Garrido-Laguna, I.; Wang, X.; Luthra, R.; Hong, D.S.; Naing, A.; Falchook, G.S.; Moroney, J.W.; Piha-Paul, S.A. et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol. Cancer Ther. 2011, 10, 558-565. [CrossRef] [PubMed]
90. Razis, E.; Bobos, M.; Kotoula, V.; Eleftheraki, A.G.; Kalofonos, H.P.; Pavlakis, K.; Papakostas, P.; Aravantinos, G.; Rigakos, G.; Efstratiou, I. et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res. Treat. 2011, 128, 447-456. [CrossRef] [PubMed]
91. Wu, I.C.; Zhao, Y.; Zhai, R.; Liu, C.Y.; Chen, F.; Ter-Minassian, M.; Asomaning, K.; Su, L.; Heist, R.S.; Kulke, M.H. et al. Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk. Carcinogenesis 2011, 32, 502-506. [CrossRef] [PubMed]
92. Agell, L.; Hernández, S.; Salido, M.; de Muga, S.; Juanpere, N.; Arumí-Uria, M.; Menendez, S.; Lorenzo, M.; Lorente, J.A.; Serrano, S. et al. PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events. Mod. Pathol. 2011, 24, 443-452. [CrossRef] [PubMed]
93. Li, S.Y.; Rong, M.; Grieu, F.; Iacopetta, B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res. Treat. 2006, 96, 91-95. [CrossRef] [PubMed]
94. Wu, G.; Mambo, E.; Guo, Z.; Hu, S.; Huang, X.; Gollin, S.M.; Trink, B.; Ladenson, P.W.; Sidransky, D.; Xing, M. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J. Clin. Endocrinol. Metab. 2005, 90, 4688-4693. [CrossRef] [PubMed]
95. Spoerke, J.M.; O’Brien, C.; Huw, L.; Koeppen, H.; Fridlyand, J.; Brachmann, R.K.; Haverty, P.M.; Pandita, A.; Mohan, S.; Sampath, D. et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin. Cancer Res. 2012, 18, 6771-5783. [CrossRef] [PubMed]
96. Pande, M.; Bondy, M.L.; Do, K.A.; Sahin, A.A.; Ying, J.; Mills, G.B.; Thompson, P.A.; Brewster, A.M. Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. Breast Cancer Res. Treat. 2014, 147, 381-387. [CrossRef] [PubMed]
97. Platt, F.M.; Hurst, C.D.; Taylor, C.F.; Gregory, W.M.; Harnden, P.; Knowles, M.A. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin. Cancer Res. 2009, 15, 6008-6017. [CrossRef] [PubMed]
98. Jiao, Y.; Shi, C.; Edil, B.H.; de Wilde, R.F.; Klimstra, D.S.; Maitra, A.; Schulick, R.D.; Tang, L.H.; Wolfgang, C.L.; Choti, M.A. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011, 331, 1199-1203. [CrossRef] [PubMed]
99. Stjernström, A.; Karlsson, C.; Fernandez, O.J.; Söderkvist, P.; Karlsson, M.G.; Thunell, L.K. Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung. Cancer Med. 2014, 3, 337-348. [CrossRef] [PubMed]
100. Mizoguchi, M.; Nutt, C.L.; Mohapatra, G.; Louis, D.N. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol. 2004, 14, 372-377. [CrossRef] [PubMed]
101. Cui, W.; Cai, Y.; Wang, W.; Liu, Z.; Wei, P.; Bi, R.; Chen, W.; Sun, M.; Zhou, X. Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma. J. Transl. Med. 2014, 12, 10. [CrossRef] [PubMed]
102. Hildebrandt, M.A.; Lippman, S.M.; Etzel, C.J.; Kim, E.; Lee, J.J.; Khuri, F.R.; Spitz, M.R.; Lotan, R.; Hong, W.K.; Wu, X. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin. Cancer Res. 2012, 18, 3705-3713. [CrossRef] [PubMed]
103. Hartmann, W.; Digon-Söntgerath, B.; Koch, A.; Waha, A.; Endl, E.; Dani, I.; Denkhaus, D.; Goodyer, C.G.; Sörensen, N.; Wiestler, O.D. et al. Phosphatidylinositol 31-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin. Cancer Res. 2006, 12, 3019-3027. [CrossRef] [PubMed]
104. Turajlic, S.; Furney, S.J.; Stamp, G.; Rana, S.; Ricken, G.; Oduko, Y.; Saturno, G.; Springer, C.; Hayes, A.; Gore, M. et al. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann. Oncol. 2014, 25, 959-967. [CrossRef] [PubMed]
105. Lu, T.P.; Lai, L.C.; Tsai, M.H.; Chen, P.C.; Hsu, C.P.; Lee, J.M.; Hsiao, C.K.; Chuang, E.Y. Integrated analyses of copy number variations and gene expression in lung adenocarcinoma. PLoS ONE 2011, 6, e24829. [CrossRef] [PubMed]
106. Choucair, K.; Ejdelman, J.; Brimo, F.; Aprikian, A.; Chevalier, S.; Lapointe, J. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. BMC Cancer 2012, 12, 543. [CrossRef] [PubMed]
107. Sircar, K.; Yoshimoto, M.; Monzon, F.A.; Koumakpayi, I.H.; Katz, R.L.; Khanna, A.; Alvarez, K.; Chen, G.; Darnel, A.D.; Aprikian, A.G. et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J. Pathol. 2009, 218, 505-513. [CrossRef] [PubMed]
108. Byun, D.S.; Cho, K.; Ryu, B.K.; Lee, M.G.; Park, J.I.; Chae, K.S.; Kim, H.J.; Chi, S.G. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int. J. Cancer 2003, 104, 318-327. [CrossRef] [PubMed]
109. Heikkinen, T.; Greco, D.; Pelttari, L.M.; Tommiska, J.; Vahteristo, P.; Heikkilä, P.; Blomqvist, C.; Aittomäki, K.; Nevanlinna, H. Variants on the promoter region of PTEN affect breast cancer progression and patient survival. Breast Cancer Res. 2011, 13, R130. [CrossRef] [PubMed]
110. Hosgood, H.D., III; Menashe, I.; He, X.; Chanock, S.; Lan, Q. PTEN identified as important risk factor of chronic obstructive pulmonary disease. Respir. Med. 2009, 103, 1866-1870. [CrossRef] [PubMed]
111. Zhou, X.P.; Waite, K.A.; Pilarski, R.; Hampel, H.; Fernandez, M.J.; Bos, C.; Dasouki, M.; Feldman, G.L.; Greenberg, L.A.; Ivanovich, J. et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am. J. Hum. Genet. 2003, 73, 404-411. [CrossRef] [PubMed]
112. Kurose, K.; Zhou, X.P.; Araki, T.; Cannistra, S.A.; Maher, E.R.; Eng, C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am. J. Pathol. 2001, 158, 2097-2106. [CrossRef]
113. Chen, M.; Cassidy, A.; Gu, J.; Delclos, G.L.; Zhen, F.; Yang, H.; Hildebrandt, M.A.; Lin, J.; Ye, Y.; Chamberlain, R.M. et al. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis 2009, 30, 2047-2052. [CrossRef] [PubMed]
114. Carracedo, A.; Salido, M.; Corominas, J.M.; Rojo, F.; Ferreira, B.I.; Suela, J.; Tusquets, I.; Corzo, C.; Segura, M.; Espinet, B. et al. Are ER + PR+ and ER + PR- breast tumors genetically different? A CGH array study. Cancer Genet. 2012, 205, 138-146. [CrossRef] [PubMed]
115. Mehta, M.S.; Vazquez, A.; Kulkarni, D.A.; Kerrigan, J.E.; Atwal, G.; Metsugi, S.; Toppmeyer, D.L.; Levine, A.J.; Hirshfield, K.M. Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes. Breast Cancer Res. Treat. 2011, 125, 861-868. [CrossRef] [PubMed]
116. Ma, X.M.; Blenis, J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 2009, 10, 307-318. [CrossRef] [PubMed]
117. Gebauer, F.; Hentze, M.W. Molecular mechanisms of translational control. Nat. Rev. Mol. Cell Biol. 2004, 5, 827-835. [CrossRef] [PubMed]
118. Gingras, A.C.; Raught, B.; Sonenberg, N. eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 1999, 68, 913-963. [CrossRef] [PubMed]
119. Martin, K.A.; Blenis, J. Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv. Cancer Res. 2002, 86, 1-39. [PubMed]
120. Avruch, J.; Belham, C.; Weng, Q.; Hara, K.; Yonezawa, K. The p70 S6 kinase integrates nutrient and growth signals to control translational capacity. Prog. Mol. Subcell. Biol. 2001, 26, 115-154. [PubMed]
121. Raught, B.; Peiretti, F.; Gingras, A.C.; Livingstone, M.; Shahbazian, D.; Mayeur, G.L.; Polakiewicz, R.D.; Sonenberg, N.; Hershey, J.W. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J. 2004, 23, 1761-1769. [CrossRef] [PubMed]
122. Tang, H.; Hornstein, E.; Stolovich, M.; Levy, G.; Livingstone, M.; Templeton, D.; Avruch, J.; Meyuhas, O. Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation. Mol. Cell. Biol. 2001, 21, 8671-8683. [CrossRef] [PubMed]
123. Ruvinsky, I.; Sharon, N.; Lerer, T.; Cohen, H.; Stolovich-Rain, M.; Nir, T.; Dor, Y.; Zisman, P.; Meyuhas, O. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev. 2005, 19, 2199-2211. [CrossRef] [PubMed]
124. Holz, M.K.; Ballif, B.A.; Gygi, S.P.; Blenis, J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005, 123, 569-580. [CrossRef] [PubMed]
125. Wang, X.; Li, W.; Williams, M.; Terada, N.; Alessi, D.R.; Proud, C.G. Regulation of elongation factor 2 kinase by p90RSK1 and p70 S6 kinase. EMBO J. 2001, 20, 4370-4379. [CrossRef] [PubMed]
126. Yang, H.S.; Jansen, A.P.; Komar, A.A.; Zheng, X.; Merrick, W.C.; Costes, S.; Lockett, S.J.; Sonenberg, N.; Colburn, N.H. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol. Cell. Biol. 2003, 23, 26-37. [CrossRef] [PubMed]
127. Dorrello, N.V.; Peschiaroli, A.; Guardavaccaro, D.; Colburn, N.H.; Sherman, N.E.; Pagano, M. S6k1-and βTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006, 314, 467-471. [CrossRef] [PubMed]
128. Richardson, C.J.; Bröenstrup, M.; Fingar, D.C.; Jülich, K.; Ballif, B.A.; Gygi, S.; Blenis, J. SKAR is a specific target of S6 kinase 1 in cell growth control. Curr. Biol. 2004, 14, 1540-1549. [CrossRef] [PubMed]
129. Ma, X.M.; Yoon, S.O.; Richardson, C.J.; Jülich, K.; Blenis, J. SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell 2008, 133, 303-313. [CrossRef] [PubMed]
130. Thoreen, C.C.; Kang, S.A.; Chang, J.W.; Liu, Q.; Zhang, J.; Gao, Y.; Reichling, L.J.; Sim, T.; Sabatini, D.M.; Gray, N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009, 284, 8023-8032. [CrossRef] [PubMed]
131. Wang, X.; Beugnet, A.; Murakami, M.; Yamanaka, S.; Proud, C.G. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol. Cell. Biol. 2005, 25, 2558-2572. [CrossRef] [PubMed]
132. Huo, Y.; Iadevaia, V.; Proud, C.G. Differing effects of rapamycin and mTOR kinase inhibitors on protein synthesis. Biochem. Soc. Trans. 2011, 39, 446-450. [CrossRef] [PubMed]
133. Yoon, D.; Pastore, Y.D.; Divoky, V.; Liu, E.; Mlodnicka, A.E.; Rainey, K.; Ponka, P.; Semenza, G.L.; Schumacher, A.; Prchal, J.T. Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J. Biol. Chem. 2006, 281, 25703-25711. [CrossRef] [PubMed]
134. Huang, L.E.; Gu, J.; Schau, M.; Bunn, H.F. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependant degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 1998, 95, 7987-7992. [CrossRef] [PubMed]
135. Semenza, G.L. HIF-1: Using two hands to flip the angiogenic switch. Cancer Met. Rev. 2000, 19, 59-65. [CrossRef]
136. Semenza, G. L. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 1999, 15, 551-578. [CrossRef] [PubMed]
137. Hudson, C.C.; Liu, M.; Chiang, G.G.; Otterness, D.M.; Loomis, D.C.; Kaper, F.; Giaccia, A.J.; Abraham, R.T. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 2002, 22, 7004-7014. [CrossRef] [PubMed]
138. Arsham, A.M.; Howell, J.J.; Simon, M.C. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J. Biol. Chem. 2003, 278, 29655-29660. [CrossRef] [PubMed]
139. Brugarolas, J.; Lei, K.; Hurley, R.L.; Manning, B.D.; Reiling, J.H.; Hafen, E.; Witters, L.A.; Ellisen, L.W.; Kaelin, W.G., Jr. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004, 18, 2893-2904. [CrossRef] [PubMed]
140. Liu, L.; Cash, T.P.; Jones, R.G.; Keith, B.; Thompson, C.B.; Simon, M.C. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol. Cell 2006, 21, 521-531. [CrossRef] [PubMed]
141. Forsythe, J.A.; Jiang, B.H.; Iyer, N.V.; Agani, F.; Leung, S.W.; Koos, R.D.; Semenza, G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16, 4604-4013. [CrossRef] [PubMed]
142. Carmeliet, P.; Ferreira, V.; Breier, G.; Pollefeyt, S.; Kieckens, L.; Gertsenstein, M.; Fahrig, M.; Vandenhoeck, A.; Harpal, K.; Eberhardt, C. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380, 435-439. [CrossRef] [PubMed]
143. Ferrara, N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 2001, 280, C1358-C1366. [PubMed]
144. Meadows, K.L.; Hurwitz, H.I. Anti-VEGF therapies in the clinic. Cold Spring Harb. Perspect. Med. 2012, 2. [CrossRef] [PubMed]
145. Presta, L.G.; Chen, H.; O’Connor, S.J.; Chisholm, V.; Meng, Y.G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997, 57, 4593-4599. [PubMed]
146. Guba, M.; von Breitenbuch, P.; Steinbauer, M.; Koehl, G.; Flegel, S.; Hornung, M.; Bruns, C.J.; Zuelke, C.; Farkas, S.; Anthuber, M. et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat. Med. 2002, 8, 128-135. [CrossRef] [PubMed]
147. Treins, C.; Giorgetti-Peraldi, S.; Murdaca, J.; Monthouël-Kartmann, M.N.; van Obberghen, E. Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor, I. Mol. Endocrinol. 2005, 19, 1304-1317. [CrossRef] [PubMed]
148. Yokogami, K.; Wakisaka, S.; Avruch, J.; Reeves, S.A. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr. Biol. 2000, 10, 47-50. [CrossRef]
149. Dodd, K.M.; Yang, J.; Shen, M.H.; Sampson, J.R.; Tee, A.R. mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 2015, 34, 2239-2250. [CrossRef] [PubMed]
150. Land, S.C.; Tee, A.R. Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J. Biol. Chem. 2007, 282, 20534-20543. [CrossRef] [PubMed]
151. Düvel, K.; Yecies, J.L.; Menon, S.; Raman, P.; Lipovsky, A.I.; Souza, A.L.; Triantafellow, E.; Ma, Q.; Gorski, R.; Cleaver, S. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010, 39, 171-183. [CrossRef] [PubMed]
152. Brugarolas, J.B.; Vazquez, F.; Reddy, A.; Sellers, W.R.; Kaelin, W.G., Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003, 4, 147-158. [CrossRef]
153. Pore, N.; Jiang, Z.; Gupta, A.; Cerniglia, G.; Kao, G.D.; Maity, A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 2006, 66, 3197-3204. [CrossRef] [PubMed]
154. Le Bacquer, O.; Petroulakis, E.; Paglialunga, S.; Poulin, F.; Richard, D.; Cianflone, K.; Sonenberg, N. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J. Clin. Investig. 2007, 117, 387-396. [CrossRef] [PubMed]
155. Kim, J.B.; Wright, H.M.; Wright, M.; Spiegelman, B.M. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc. Natl. Acad. Sci. USA 1998, 95, 4333-4337. [CrossRef] [PubMed]
156. Kim, J.E.; Chen, J. Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 2004, 53, 2748-2756. [CrossRef] [PubMed]
157. Caron, A.; Richard, D.; Laplante, M. The Roles of mTOR Complexes in Lipid Metabolism. Annu. Rev. Nutr. 2015, 35, 321-348. [CrossRef] [PubMed]
158. Wang, B.T.; Ducker, G.S.; Barczak, A.J.; Barbeau, R.; Erle, D.J.; Shokat, K.M. The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Proc. Natl. Acad. Sci. USA 2011, 108, 15201-15206. [CrossRef] [PubMed]
159. Owen, J.L.; Zhang, Y.; Bae, S.H.; Farooqi, M.S.; Liang, G.; Hammer, R.E.; Goldstein, J.L.; Brown, M.S. Insulin stimulation of SREBP-1c processing in transgenic rat hepatocytes requires p70 S6-kinase. Proc. Natl. Acad. Sci. USA 2012, 109, 16184-16189. [CrossRef] [PubMed]
160. Kammoun, H.L.; Chabanon, H.; Hainault, I.; Luquet, S.; Magnan, C.; Koike, T.; Ferré, P.; Foufelle, F. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J. Clin. Investig. 2009, 119, 1201-1215. [CrossRef] [PubMed]
161. Werstuck, G.H.; Lentz, S.R.; Dayal, S.; Hossain, G.S.; Sood, S.K.; Shi, Y.Y.; Zhou, J.; Maeda, N.; Krisans, S.K.; Malinow, M.R. et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J. Clin. Investig. 2001, 107, 1263-1273. [CrossRef] [PubMed]
162. Koh, Y.K.; Lee, M.Y.; Kim, J.W.; Kim, M.; Moon, J.S.; Lee, Y.J.; Ahn, Y.H.; Kim, K.S. Lipin1 is a key factor for the maturation and maintenance of adipocytes in the regulatory network with CCAAT/enhancer-binding protein α and peroxisome proliferator-activated receptor gamma 2. J. Biol. Chem. 2008, 283, 34896-34906. [CrossRef] [PubMed]
163. Huffman, T.A.; Mothe-Satney, I.; Lawrence, J.C., Jr. Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc. Natl. Acad. Sci. USA 2002, 99, 1047-1052. [CrossRef] [PubMed]
164. Peterson, T.R.; Sengupta, S.S.; Harris, T.E.; Carmack, A.E.; Kang, S.A.; Balderas, E.; Guertin, D.A.; Madden, K.L.; Carpenter, A.E.; Finck, B.N. et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011, 146, 408-420. [CrossRef] [PubMed]
165. Zoncu, R.; Efeyan, A.; Sabatini, D.M. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12, 21-35. [CrossRef] [PubMed]
166. Yabe, D.; Komuro, R.; Liang, G.; Goldstein, J.L.; Brown, M.S. Liver-specific mRNA for Insig-2 downregulated by insulin: Implications for fatty acid synthesis. Proc. Natl. Acad. Sci. USA 2003, 100, 3155-3160. [CrossRef] [PubMed]
167. Yellaturu, C.R.; Deng, X.; Park, E.A.; Raghow, R.; Elam, M.B. Insulin enhances the biogenesis of nuclear sterol regulatory element-binding protein (SREBP)-1c by posttranscriptional downregulation of Insig-2A and its dissociation from SREBP cleavage-activating protein (SCAP)¨ SREBP-1c complex. J. Biol. Chem. 2009, 284, 31726-31734. [CrossRef] [PubMed]
168. Yellaturu, C.R.; Deng, X.; Cagen, L.M.; Wilcox, H.G.; Mansbach, C.M., II; Siddiqi, S.A.; Park, E.A.; Raghow, R.; Elam, M.B. Insulin enhances post-translational processing of nascent SREBP-1c by promoting its phosphorylation and association with COPII vesicles. J. Biol. Chem. 2009, 284, 7518-7532. [CrossRef] [PubMed]
169. Bengoechea-Alonso, M.T.; Ericsson, J. A phosphorylation cascade controls the degradation of active SREBP1. J. Biol. Chem. 2009, 284, 5885-5895. [CrossRef] [PubMed]
170. Porstmann, T.; Santos, C.R.; Griffiths, B.; Cully, M.; Wu, M.; Leevers, S.; Griffiths, J.R.; Chung, Y.L.; Schulze, A. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008, 8, 224-236. [CrossRef] [PubMed]
171. Zhang, H.H.; Huang, J.; Düvel, K.; Boback, B.; Wu, S.; Squillace, R.M.; Wu, C.L.; Manning, B.D. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS ONE 2009, 4, e6189. [CrossRef] [PubMed]
172. Cho, H.J.; Park, J.; Lee, H.W.; Lee, Y.S.; Kim, J.B. Regulation of adipocyte differentiation and insulin action with rapamycin. Biochem. Biophys. Res. Commun. 2004, 321, 942-948. [CrossRef] [PubMed]
173. Ricoult, S.J.; Manning, B.D. The multifaceted role of mTORC1 in the control of lipid metabolism. EMBO Rep. 2013, 14, 242-251. [CrossRef] [PubMed]
174. Bell, A.; Grunder, L.; Sorisky, A. Rapamycin inhibits human adipocyte differentiation in primary culture. Obes. Res. 2000, 8, 249-254. [CrossRef] [PubMed]
175. Gagnon, A.; Lau, S.; Sorisky, A. Rapamycin-sensitive phase of 3T3-L1 preadipocyte differentiation after clonal expansion. J. Cell. Physiol. 2001, 189, 14-22. [CrossRef] [PubMed]
176. El-Chaâr, D.; Gagnon, A.; Sorisky, A. Inhibition of insulin signaling and adipogenesis by rapamycin: Effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1. Int. J. Obes. Relat. Metab. Disord. 2004, 28, 191-198. [CrossRef] [PubMed]
177. Polak, P.; Cybulski, N.; Feige, J.N.; Auwerx, J.; Ruegg, M.A.; Hall, M.N. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab. 2008, 8, 399-410. [CrossRef] [PubMed]
178. Yeh, W.C.; Bierer, B.E.; McKnight, S.L. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. Proc. Natl. Acad. Sci. USA 1995, 92, 11086-11090. [CrossRef] [PubMed]
179. Kiberd, B.A. Cardiovascular risk reduction in renal transplantation: Strategies for success. Minerva Urol. Nefrol. 2002, 54, 51-63. [PubMed]
180. Flechner, S.M.; Glyda, M.; Cockfield, S.; Grinyó, J.; Legendre, C.; Russ, G.; Steinberg, S.; Wissing, K.M.; Tai, S.S. The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am. J. Transplant. 2011, 11, 1633-1644. [CrossRef] [PubMed]
181. Brattström, C.; Wilczek, H.; Tydén, G.; Böttiger, Y.; Säwe, J.; Groth, C.G. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998, 65, 1272-1274. [CrossRef] [PubMed]
182. Ekberg, H.; Bernasconi, C.; Nöldeke, J.; Yussim, A.; Mjörnstedt, L.; Erken, U.; Ketteler, M.; Navrátil, P. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol. Dial. Transplant. 2010, 25, 2004-2010. [CrossRef] [PubMed]
183. Hoogeveen, R.C.; Ballantyne, C.M.; Pownall, H.J.; Opekun, A.R.; Hachey, D.L.; Jaffe, J.S.; Oppermann, S.; Kahan, B.D.; Morrisett, J.D. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation 2001, 72, 1244-1250. [CrossRef] [PubMed]
184. Morrisett, J.D.; Abdel-Fattah, G.; Hoogeveen, R.; Mitchell, E.; Ballantyne, C.M.; Pownall, H.J.; Opekun, A.R.; Jaffe, J.S.; Oppermann, S.; Kahan, B.D. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J. Lipid Res. 2002, 43, 1170-1180. [PubMed]
185. Blanchard, P.G.; Festuccia, W.T.; Houde, V.P.; St-Pierre, P.; Brûlé, S.; Turcotte, V.; Côté, M.; Bellmann, K.; Marette, A.; Deshaies, Y. Major involvement of mTOR in the PPARγ-induced stimulation of adipose tissue lipid uptake and fat accretion. J. Lipid Res. 2012, 53, 1117-1125. [CrossRef] [PubMed]
186. Kelly, D.P.; Scarpulla, R.C. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 2004, 18, 357-368. [CrossRef] [PubMed]
187. Belandia, B.; Parker, M.G. Nuclear receptors: A rendezvous for chromatin remodeling factors. Cell 2003, 114, 277-280. [CrossRef]
188. Morita, M.; Gravel, S.P.; Chénard, V.; Sikström, K.; Zheng, L.; Alain, T.; Gandin, V.; Avizonis, D.; Arguello, M.; Zakaria, C. et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 2013, 18, 698-711. [CrossRef] [PubMed]
189. Schieke, S.M.; Phillips, D.; McCoy, J.P., Jr.; Aponte, A.M.; Shen, R.F.; Balaban, R.S.; Finkel, T. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J. Biol. Chem. 2006, 281, 27643-27652. [CrossRef] [PubMed]
190. Cunningham, J.T.; Rodgers, J.T.; Arlow, D.H.; Vazquez, F.; Mootha, V.K.; Puigserver, P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1α transcriptional complex. Nature 2007, 450, 736-740. [CrossRef] [PubMed]
191. Desai, B.N.; Myers, B.R.; Schreiber, S.L. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc. Natl. Acad. Sci. USA 2002, 99, 4319-4324. [CrossRef] [PubMed]
192. Ramanathan, A.; Schreiber, S.L. Direct control of mitochondrial function by mTOR. Proc. Natl. Acad. Sci. USA 2009, 106, 22229-22232. [CrossRef] [PubMed]
193. Fingar, D.C.; Salama, S.; Tsou, C.; Harlow, E.; Blenis, J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002, 16, 1472-1487. [CrossRef] [PubMed]
194. Fingar, D.C.; Richardson, C.J.; Tee, A.R.; Cheatham, L.; Tsou, C.; Blenis, J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 2004, 24, 200-216. [CrossRef] [PubMed]
195. Tzivion, G.; Dobson, M.; Ramakrishnan, G. Fox O transcription factors; Regulation by AKT and 14-3-3 proteins. Biochim. Biophys. Acta 2011, 1813, 1938-1945. [CrossRef] [PubMed]
196. Cybulski, N.; Hall, M.N. TOR complex 2: A signaling pathway of its own. Trends Biochem. Sci. 2009, 34, 620-627. [CrossRef] [PubMed]
197. Brunet, A.; Park, J.; Tran, H.; Hu, L.S.; Hemmings, B.A.; Greenberg, M.E. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell. Biol. 2001, 21, 952-965. [CrossRef] [PubMed]
198. Gao, D.; Wan, L.; Inuzuka, H.; Berg, A.H.; Tseng, A.; Zhai, B.; Shaik, S.; Bennett, E.; Tron, A.E.; Gasser, J.A. et al. Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction. Mol. Cell 2010, 39, 797-808. [CrossRef] [PubMed]
199. Mori, S.; Nada, S.; Kimura, H.; Tajima, S.; Takahashi, Y.; Kitamura, A.; Oneyama, C.; Okada, M. The mTOR pathway controls cell proliferation by regulating the FoxO3a transcription factor via SGK1 kinase. PLoS ONE 2014, 9, e88891. [CrossRef] [PubMed]
200. Mizushima, N.; Komatsu, M. Autophagy: Renovation of cells and tissues. Cell 2011, 147, 728-741. [PubMed]
201. Jung, C.H.; Ro, S.H.; Cao, J.; Otto, N.M.; Kim, D.H. mTOR regulation of autophagy. FEBS Lett. 2010, 584, 1287-1295. [CrossRef] [PubMed]
202. Glick, D.; Barth, S.; Macleod, K.F. Autophagy: Cellular and molecular mechanisms. J. Pathol. 2010, 221, 3-12. [CrossRef] [PubMed]
203. Hosokawa, N.; Hara, T.; Kaizuka, T.; Kishi, C.; Takamura, A.; Miura, Y.; Iemura, S.; Natsume, T.; Takehana, K.; Yamada, N. et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol. Biol. Cell 2009, 20, 1981-1991. [CrossRef] [PubMed]
204. Jung, C.H.; Jun, C.B.; Ro, S.H.; Kim, Y.M.; Otto, N.M.; Cao, J.; Kundu, M.; Kim, D.H. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol. Biol. Cell 2009, 20, 1992-2003. [CrossRef] [PubMed]
205. Ganley, I.G.; Lam du, H.; Wang, J.; Ding, X.; Chen, S.; Jiang, X. ULK1 ATG13 FIP200 complex mediates mTOR signaling and is essential for autophagy. J. Biol. Chem. 2009, 284, 12297-12305. [CrossRef] [PubMed]
206. Nazio, F.; Strappazzon, F.; Antonioli, M.; Bielli, P.; Cianfanelli, V.; Bordi, M.; Gretzmeier, C.; Dengjel, J.; Piacentini, M.; Fimia, G.M. et al. mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Nat. Cell Biol. 2013, 15, 406-416. [CrossRef] [PubMed]
207. Settembre, C.; Fraldi, A.; Medina, D.L.; Ballabio, A. Signals from the lysosome: A control centre for cellular clearance and energy metabolism. Nat. Rev. Mol. Cell Biol. 2013, 14, 283-296. [CrossRef] [PubMed]
208. Peña-Llopis, S.; Vega-Rubin-de-Celis, S.; Schwartz, J.C.; Wolff, N.C.; Tran, T.A.; Zou, L.; Xie, X.J.; Corey, D.R.; Brugarolas, J. Regulation of TFEB and V-ATPases by mTORC1. EMBO J. 2011, 30, 3242-3258. [CrossRef] [PubMed]
209. Settembre, C.; Di Malta, C.; Polito, V.A.; Garcia Arencibia, M.; Vetrini, F.; Erdin, S.; Erdin, S.U.; Huynh, T.; Medina, D.; Colella, P. et al. TFEB links autophagy to lysosomal biogenesis. Science 2011, 332, 1429-1433. [CrossRef] [PubMed]
210. Settembre, C.; Zoncu, R.; Medina, D.L.; Vetrini, F.; Erdin, S.; Erdin, S.; Huynh, T.; Ferron, M.; Karsenty, G.; Vellard, M.C. et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 2012, 31, 1095-1108. [CrossRef] [PubMed]
211. Yu, L.; McPhee, C.K.; Zheng, L.; Mardones, G.A.; Rong, Y.; Peng, J.; Mi, N.; Zhao, Y.; Liu, Z.; Wan, F. et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 2010, 465, 942-946. [CrossRef] [PubMed]
212. Cao, C.; Subhawong, T.; Albert, J.M.; Kim, K.W.; Geng, L.; Sekhar, K.R.; Gi, Y.J.; Lu, B. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006, 66, 10040-10047. [CrossRef] [PubMed]
213. Filipowicz, W.; Jaskiewicz, L.; Kolb, F.A.; Pillai, R.S. Post-transcriptional gene silencing by siRNAs and miRNAs. Curr. Opin. Struct. Biol. 2005, 15, 331-341. [CrossRef] [PubMed]
214. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281-297. [CrossRef]
215. Rukov, J.L.; Shomron, N. MicroRNA pharmacogenomics: Post-transcriptional regulation of drug response. Trends Mol. Med. 2011, 17, 412-423. [CrossRef] [PubMed]
216. Totary-Jain, H.; Sanoudou, D.; Ben-Dov, I.Z.; Dautriche, C.N.; Guarnieri, P.; Marx, S.O.; Tuschl, T.; Marks, A.R. Reprogramming of the microRNA transcriptome mediates resistance to rapamycin. J. Biol. Chem. 2013, 288, 6034-6044. [CrossRef] [PubMed]
217. Santulli, G.; Totary-Jain, H. Tailoring mTOR-based therapy: Molecular evidence and clinical challenges. Pharmacogenomics 2013, 14, 1517-1526. [CrossRef] [PubMed]
218. Zou, Z.; Chen, J.; Liu, A.; Zhou, X.; Song, Q.; Jia, C.; Chen, Z.; Lin, J.; Yang, C.; Li, M. et al. mTORC2 promotes cell survival through c-Myc-dependent upregulation of E2F1. J. Cell Biol. 2015, 211, 105-122. [CrossRef] [PubMed]
219. Jin, C.; Zhao, Y.; Yu, L.; Xu, S.; Fu, G. MicroRNA-21 mediates the rapamycin-induced suppression of endothelial proliferation and migration. FEBS Lett. 2013, 587, 378-385. [CrossRef] [PubMed]
220. Jin, X.L.; Sun, Q.S.; Liu, F.; Yang, H.W.; Liu, M.; Liu, H.X.; Xu, W.; Jiang, Y.Y. microRNA 21-mediated suppression of Sprouty1 by Pokemon affects liver cancer cell growth and proliferation. J. Cell. Biochem. 2013, 114, 1625-1633. [CrossRef] [PubMed]
221. Papadopoulos, E.I.; Yousef, G.M.; Scorilas, A. Cytotoxic activity of sunitinib and everolimus in Caki-1 renal cancer cells is accompanied by modulations in the expression of apoptosis-related microRNA clusters and BCL2 family genes. Biomed. Pharmacother. 2015, 70, 33-40. [CrossRef] [PubMed]
222. Sun, Y.; Ge, Y.; Drnevich, J.; Zhao, Y.; Band, M.; Chen, J. Mammalian target of rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis. J. Cell Biol. 2010, 189, 1157-1169. [CrossRef] [PubMed]
223. Fang, Y.; Xue, J.L.; Shen, Q.; Chen, J.; Tian, L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology 2012, 55, 1852-1862. [CrossRef] [PubMed]
224. Cui, L.; Zhou, H.; Zhao, H.; Zhou, Y.; Xu, R.; Xu, X.; Zheng, L.; Xue, Z.; Xia, W.; Zhang, B. et al. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer 2012, 12, 546. [CrossRef] [PubMed]
225. Yan, B.; Fu, Q.; Lai, L.; Tao, X.; Fei, Y.; Shen, J.; Chen, Z.; Wang, Q. Downregulation of microRNA 99a in oral squamous cell carcinomas contributes to the growth and survival of oral cancer cells. Mol. Med. Rep. 2012, 6, 675-681. [PubMed]
226. Oneyama, C.; Ikeda, J.; Okuzaki, D.; Suzuki, K.; Kanou, T.; Shintani, Y.; Morii, E.; Okumura, M.; Aozasa, K.; Okada, M. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 2011, 30, 3489-3501. [CrossRef] [PubMed]
227. Wang, Y.; Liu, J.; Liu, C.; Naji, A.; Stoffers, D.A. MicroRNA-7 regulates the mTOR pathway and proliferation in adult pancreatic β-cells. Diabetes 2013, 62, 887-895. [CrossRef] [PubMed]
228. Iwaya, T.; Yokobori, T.; Nishida, N.; Kogo, R.; Sudo, T.; Tanaka, F.; Shibata, K.; Sawada, G.; Takahashi, Y.; Ishibashi, M. et al. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis 2012, 33, 2391-2397. [CrossRef] [PubMed]
229. Uesugi, A.; Kozaki, K.; Tsuruta, T.; Furuta, M.; Morita, K.; Imoto, I.; Omura, K.; Inazawa, J. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 2011, 71, 5765-5778. [CrossRef] [PubMed]
230. Grundmann, S.; Hans, F.P.; Kinniry, S.; Heinke, J.; Helbing, T.; Bluhm, F.; Sluijter, J.P.; Hoefer, I.; Pasterkamp, G.; Bode, C. et al. MicroRNA-100 regulates neovascularization by suppression of mammalian target of rapamycin in endothelial and vascular smooth muscle cells. Circulation 2011, 123, 999-1009. [CrossRef] [PubMed]
231. Nagaraja, A.K.; Creighton, C.J.; Yu, Z.; Zhu, H.; Gunaratne, P.H.; Reid, J.G.; Olokpa, E.; Itamochi, H.; Ueno, N.T.; Hawkins, S.M. et al. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol. Endocrinol. 2010, 24, 447-463. [CrossRef] [PubMed]
232. Sun, J.; Chen, Z.; Tan, X.; Zhou, F.; Tan, F.; Gao, Y.; Sun, N.; Xu, X.; Shao, K.; He, J. MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. Med. Oncol. 2013, 30, 411. [CrossRef] [PubMed]
233. Zaza, G.; Granata, S.; Tomei, P.; Dalla Gassa, A.; Lupo, A. Personalization of the immunosuppressive treatment in renal transplant recipients: The great challenge in “omics” medicine. Int. J. Mol. Sci. 2015, 16, 4281-4305. [CrossRef] [PubMed]
234. Renders, L.; Frisman, M.; Ufer, M.; Mosyagin, I.; Haenisch, S.; Ott, U.; Caliebe, A.; Dechant, M.; Braun, F.; Kunzendorf, U. et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin. Pharmacol. Ther. 2007, 81, 228-234. [CrossRef] [PubMed]
235. Le Meur, Y.; Djebli, N.; Szelag, J.C.; Hoizey, G.; Toupance, O.; Rérolle, J.P.; Marquet, P. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin. Pharmacol. Ther. 2006, 80, 51-60. [CrossRef] [PubMed]
236. Mourad, M.; Mourad, G.; Wallemacq, P.; Garrigue, V.; van Bellingen, C.; van Kerckhove, V.; de Meyer, M.; Malaise, J.; Eddour, D.C.; Lison, D. et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005, 80, 977-984. [CrossRef] [PubMed]
237. Zaza, G.; Granata, S.; Sallustio, F.; Grandaliano, G.; Schena, F.P. Pharmacogenomics: A new paradigm to personalize treatments in nephrology patients. Clin. Exp. Immunol. 2010, 159, 268-280. [CrossRef] [PubMed]
238. Anglicheau, D.; Le Corre, D.; Lechaton, S.; Laurent-Puig, P.; Kreis, H.; Beaune, P.; Legendre, C.; Thervet, E. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am. J. Transplant. 2005, 5, 595-603. [CrossRef] [PubMed]
239. Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P.B.; Daly, A.; Wrighton, S.A.; Hall, S.D. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 2001, 27, 383-391. [CrossRef] [PubMed]
240. Picard, N.; Rouguieg-Malki, K.; Kamar, N.; Rostaing, L.; Marquet, P. CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. Transplantation 2011, 91, 652-656. [CrossRef] [PubMed]
241. Kniepeiss, D.; Renner, W.; Trummer, O.; Wagner, D.; Wasler, A.; Khoschsorur, G.A.; Truschnig-Wilders, M.; Tscheliessnigg, K.H. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clin. Transplant. 2011, 25, 146-150. [CrossRef] [PubMed]
242. Sam, W.J.; Chamberlain, C.E.; Lee, S.J.; Goldstein, J.A.; Hale, D.A.; Mannon, R.B.; Kirk, A.D.; Hon, Y.Y. Associations of ABCB1 3435C>T and IL-10 -1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients. Transplantation 2011, 92, 1342-1347. [CrossRef] [PubMed]
243. Abdel-Razzak, Z.; Loyer, P.; Fautrel, A.; Gautier, J.C.; Corcos, L.; Turlin, B.; Beaune, P.; Guillouzo, A. Cytokines downregulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol. Pharmacol. 1993, 44, 707-715. [PubMed]
244. Bertilsson, P.M.; Olsson, P.; Magnusson, K.E. Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells. J. Pharm. Sci. 2001, 90, 638-646. [CrossRef]
245. Miao, L.Y.; Huang, C.R.; Hou, J.Q.; Qian, M.-Y. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm. Drug Dispos. 2008, 29, 1-5. [CrossRef] [PubMed]